ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
25.12
-0.08 (-0.32%)
Jan 23, 2026, 10:47 AM EST - Market open
ArriVent BioPharma Employees
ArriVent BioPharma had 52 employees as of December 31, 2024. The number of employees increased by 12 or 30.00% compared to the previous year.
Employees
52
Change (1Y)
12
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$2,903,423
Market Cap
1.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
| Sep 30, 2023 | 42 | - | - |
| Jun 30, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Maravai LifeSciences Holdings | 570 |
| Vir Biotechnology | 408 |
| ARS Pharmaceuticals | 167 |
| Zenas BioPharma | 130 |
| Nanobiotix | 103 |
| Annexon | 99 |
| Theravance Biopharma | 97 |
AVBP News
- 19 days ago - ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy - Seeking Alpha
- 4 weeks ago - ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts - Seeking Alpha
- 4 weeks ago - ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - ArriVent BioPharma Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - ArriVent Appoints Brent S. Rice as Chief Commercial Officer - GlobeNewsWire
- 4 months ago - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 5 months ago - ArriVent BioPharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - GlobeNewsWire